Regulatory changes in the US such as the risk evaluation and mitigation strategies required by the Food and Drug Administration Amendments Act of 2007 are having a profound effect on drug review times and on review outcomes, a white paper from PAREXEL Consulting has revealed1
...
Please login to read the full article.
